TransCode Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
TransCode Therapeutics, Inc., a Delaware biotechnology company, filed this Current Report on Form 8-K on December 9, 2022, regarding a Nasdaq continued-listing deficiency. Its common stock trades under the symbol RNAZ on The Nasdaq Capital Market.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial metrics.
Material Change Versus Prior Period
Nasdaq notified the company that its common stock failed to maintain the required minimum closing bid price of $1.00 per share for 30 consecutive business days from October 27, 2022 through December 8, 2022. The notice did not immediately delist the company’s stock.
Compliance Timeline, Outlook, and Risks
- The company received an initial 180-calendar-day compliance period ending June 7, 2023.
- To regain compliance, the stock must close at or above $1.00 per share for at least 10 consecutive business days, subject to Nasdaq’s determination.
- If the company does not regain compliance by June 7, 2023, it may qualify for an additional 180-calendar-day period if it meets applicable market value and other initial Nasdaq listing standards and formally requests the additional period.
- If Nasdaq determines that the deficiency cannot be cured, the company may receive a delisting notice and may appeal to a Nasdaq Hearing Panel. The company expects its stock would remain listed while an appeal is pending, but there is no assurance that an appeal would succeed.
- Management intends to monitor the stock price and may consider measures including a reverse stock split. There is no assurance that the company will regain compliance, obtain an additional compliance period, or satisfy other Nasdaq continued-listing requirements.
Important Facts for Investors to Verify
- Whether RNAZ regained compliance with Nasdaq’s $1.00 minimum bid price requirement by June 7, 2023.
- Whether Nasdaq granted an additional compliance period or issued a delisting determination.
- Whether the company pursued a reverse stock split or another corporate action to address the deficiency.
- The company’s subsequent Nasdaq listing status and any related effects on trading liquidity and investor access.